Abstract
A five-year follow-up is presented of 123 patients with recently diagnosed prostatic cancer, confirmed histopathologically and treated with fosfestrol and bromocriptine. The combined treatment has been shown to prevent most of the complications and side effects of therapy, thus it is considered to be worthy of recommendation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Adler, A., Burger, H., Davis, J., Dulmanis, A., Hudson, B., Sarfaty, G., Straffon, W.: Carcinoma of prostate: Response of plasma luteinizing hormone and testosterone to oestrogen therapy.Br. Med. J., 1, 28 (1968).
Asano, M., Konzaki, S., Sekiguchi, E., Tasaka, T.: Inhibition of prostatic growth in rabbits with antiovine prolactin serum.J. Urol., 106, 248 (1971).
Bacz, A.: Bromocriptine—a new drug in gynecology and obstetrics.Gin. Pol., 53, 291 (1982).
Blackard, C. E., Doc, R. P., Mellinger, G. T., Byar, D. P.: Incidence of cardiovascular disease and death in patients receiving diethylstilboestrol for carcinoma of the prostate.Cancer, 26, 249 (1970).
Blüm, V.: Prolactin: Phylogenetische Aspekte.Gynäkologe, 10, 51 (1977).
Byard, D. P.: The Veterans Administration Cooperative Urological Research Groups studies of cancer of the prostate.Cancer, 32, 1126 (1973).
Flocks, R. H.: Carcinoma of the prostate.J. Urol., 101, 741 (1968).
Flöckiger, E.: Effects of bromocriptine on the hypothalamopituitary axis.Acta Endocrinol., 88, 111, Suppl. 216 (1978).
Gagnon, J., Moss, W. T., Stevens, K. R.: Pre-oestrogen breast irradiation for patients with carcinoma of the prostate: a critical review.J. Urol., 121, 182 (1979).
Hachmeister, U.: Hyperplasia of prolactin cells after oestrogen therapy in carcinoma of the prostate.Verh. Dtsch. Ges. Pathol., 56, 535 (1972).
Héritier, P., Hessler, D.: Les complications cardiovasculaires du traitment oestrogenique du cancer de la prostate.Rev. Thérap., 35, 841 (1973).
Huggins, C., Hodges, C. V.: The effect of castration of oestrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate.Cancer Research, 1, 293 (1941).
Ishibe, T.: Effect of long-term oestrogen treatment on liver function in patients with prostatic carcinoma.J. Urol., 113, 829 (1975).
Jeromin, L.: Bromocriptine use in the treatment of prostatic carcinoma.Urol. Pol., 3–4, 141 (1982).
Jeromin, L.: The use of bromocriptine and fostrolin in the treatment of prostatic carcinoma with relation to serum concentrations of testosterone and prolactin.Pol. Tyg. Lek., 35, 359 (1980).
Jeromin, L.: The role of bromocriptine in prostatic cancer.Pol. Tyg. Lek., 35, 453 (1980).
Jeromin, L.: Testosterone metabolism in prostatic cancer.Urol. Pol., 3–4, 135 (1982).
Jeske, W.: The pharmacological properties of bromocriptine and its clinical application.Pol. Tyg. Lek., 37, 653 (1982).
Nillins, S. J.: Prolactin.Acta Endocrinol., 88, 99, Suppl. 216 (1978).
Pawlikowski, M., Stępień, H., Wolaniuk, A.: The neurotransmission in the hypothalamo-pituitary axis and its role in the control of the anterior pituitary secretion.Endokrynol. Pol., 28, 461 (1977).
Author information
Authors and Affiliations
Additional information
Fosfestrol; homologues—Fostrolin (Polfa), Honvan (Asta), Stilphostrol (Dohme) Bromocriptine; homologues—Parloder (Sandoz), Pravidel (Sandoz).
Rights and permissions
About this article
Cite this article
Jeromin, L., Wiśniewski, J., Rożniecki, M. et al. Five-year clinical follow-up of prostatic cancer patients treated with fosfestrol and bromocriptine. International Urology and Nephrology 19, 81–85 (1987). https://doi.org/10.1007/BF02549682
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02549682